Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 5/20 | 0.54 |
| ▸ | PRCP | P42785 | 1/20 | 0.45 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | CD44 | P16070 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3177381 | 0.89 | PNMT (0.67) | PNMTPRCPNISCHCD44HTR2C | |
| Hydrochloric Acid SCHEMBL18009924 | 0.87 | PNMT (0.65) | PNMTPRCPNISCHCD44HTR2C | |
| SCHEMBL24265584 | 0.85 | CD44 (0.49) | PNMTNISCHCD44HTR2CMAOB | |
| SCHEMBL384797 | 0.78 | PNMT (0.44) | PNMTPRCPNISCHCD44HTR2C | |
| SCHEMBL14692360 | 0.78 | PNMT (0.50) | PNMTPRCPCD44HTR2CMAOB | |
| SCHEMBL11327500 | 0.78 | PNMT (0.50) | PNMTPRCPCD44HTR2CMAOB | |
| SCHEMBL11597488 | 0.78 | BCL2L1 (0.60) | PNMTPRCPCD44HTR2C | |
| SCHEMBL19684566 | 0.78 | PNMT (0.50) | PNMTPRCPCD44HTR2CMAOB | |
| SCHEMBL11331868 | 0.78 | PNMT (0.79) | PNMTPRCPCD44HTR2CHTR2B | |
| SCHEMBL11327051 | 0.78 | CD44 (0.62) | PNMTPRCPCD44HTR2CMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| CN-116507326-A | Compounds as GLP-1R agonists | 拓臻制药公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2022040600-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| EP-2373163-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2015-06-10 | — | — | EP | disclosed |
| US-8232273-B2 | Heterocyclic compounds and methods of use | GENENTECH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232273-B2 | Heterocyclic compounds and methods of use | GENENTECH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-08-19 | — | — | US | disclosed |
| WO-2010080503-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-0002624-B1 | 2-BENZAZEPINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BECKMAN CORPORATION (US) | 1981-10-14 | — | — | EP | disclosed |
| EP-0002624-A1 | 2-Benzazepine compounds, processes for their preparation and pharmaceutical compositions containing them | SMITHKLINE BECKMAN CORPORATION (US) | 1979-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BCL2A1, BAX, BCL2 | PNMT 3968/4885PRCP 2100/4885NISCH 3542/4885 |
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | PNMT 3066/4885PRCP 726/4885NISCH 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.